Atea Pharmaceuticals (AVIR) Interest & Investment Income (2019 - 2026)
Atea Pharmaceuticals' (AVIR) quarterly Interest & Investment Income came in at $2.6 million in Q1 2026, up 2376.52% year-on-year from $105712.8 in Q1 2025, and down 84.01% quarter-over-quarter from $16.4 million in Q4 2025.
Atea Pharmaceuticals (AVIR) Interest & Investment Income (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 2376.52% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $23.6 million, a 24.22% decrease from a year earlier, with the FY2025 full-year figure at $16.4 million, down 35.76% from the prior year.
- Interest & Investment Income eased to $2.6 million in Q1 2026 per AVIR's latest filing, from $16.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $25.1 million in Q4 2024 and bottomed at -$388000.0 in Q1 2024.
- The 5-year median for Interest & Investment Income is $377000.0 (2023), against an average of $3.6 million.
- Biggest YoY gain for Interest & Investment Income was 12977.08% in 2024; the steepest drop was 3200.0% in 2024.
- Year by year, Interest & Investment Income stood at $171000.0 in 2022, then soared by 174.27% to $469000.0 in 2023, then surged by 5242.43% to $25.1 million in 2024, then plunged by 34.66% to $16.4 million in 2025, then tumbled by 84.01% to $2.6 million in 2026.
- Per Business Quant, the three latest AVIR Interest & Investment Income figures stand at $2.6 million (Q1 2026), $16.4 million (Q4 2025), and $201000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Atea Pharmaceuticals | 382.53 Mn | 382.53 Mn | - | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 16.37 Mn |
| Sep 30, 2025 | 201,000.00 |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | -115,000.00 |
| Dec 31, 2024 | 25.06 Mn |
| Sep 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | -99,000.00 |
| Mar 31, 2024 | -388,000.00 |
| Dec 31, 2023 | 469,000.00 |
| Sep 30, 2023 | 48,000.00 |
| Jun 30, 2023 | -3,000.00 |
| Mar 31, 2023 | 377,000.00 |
| Dec 31, 2022 | 171,000.00 |
| Sep 30, 2022 | 4.38 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 98,000.00 |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 53,000.00 |
| Jun 30, 2021 | 52,000.00 |